NovaBay Pharmaceuticals Special Meeting Adjourned
Ticker: NBY · Form: DEFA14A · Filed: Nov 26, 2024 · CIK: 1389545
Sentiment: neutral
Topics: proxy-statement, adjourned-meeting, shareholder-vote
Related Tickers: NBY
TL;DR
NovaBay meeting adjourned, still need your vote!
AI Summary
NovaBay Pharmaceuticals, Inc. filed a Definitive Additional Materials document (DEFA14A) on November 26, 2024, regarding a special meeting of stockholders. The filing indicates that the special meeting was adjourned and that stockholder votes are still needed. The company is incorporated in Delaware and its fiscal year ends on December 31st.
Why It Matters
This filing signals an ongoing corporate action requiring shareholder participation, potentially impacting the company's future strategic decisions or governance.
Risk Assessment
Risk Level: medium — Adjourned meetings can indicate unresolved issues or a lack of shareholder consensus, which may pose risks to the company's operations or strategic direction.
Key Players & Entities
- NovaBay Pharmaceuticals, Inc. (company) — Registrant
- 0001389545 (company) — Central Index Key
- 2000 POWELL STREET, SUITE 1150 (company) — Business Address
- EMERYVILLE (company) — Business City
- CA (company) — Business State
- 94608 (company) — Business Zip
- (510) 899-8800 (company) — Business Phone
FAQ
What is the purpose of this DEFA14A filing?
This filing is a Definitive Additional Materials document related to a special meeting of NovaBay Pharmaceuticals, Inc. stockholders, indicating the meeting was adjourned and further votes are required.
When was this filing made?
The filing was made on November 26, 2024.
What does the adjournment of the special meeting imply?
The adjournment implies that the business intended to be conducted at the special meeting could not be completed, likely due to insufficient votes or the need for further discussion or action.
What is NovaBay Pharmaceuticals, Inc.'s fiscal year end?
NovaBay Pharmaceuticals, Inc.'s fiscal year ends on December 31st.
What is the company's primary industry classification?
The company's Standard Industrial Classification is Pharmaceutical Preparations [2834].
Filing Stats: 451 words · 2 min read · ~2 pages · Grade level 12.6 · Accepted 2024-11-26 16:08:49
Filing Documents
- nby20241125_defa14a.htm (DEFA14A) — 15KB
- nby20241125_defa14aimg001.jpg (GRAPHIC) — 5KB
- nby20241125_defa14aimg002.jpg (GRAPHIC) — 2KB
- 0001437749-24-036267.txt ( ) — 25KB
From the Filing
nby20241114_defa14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to 240.14a-12 NOVABAY PHARMACEUTICALS, INC. (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required Fee paid previously with preliminary materials Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 *** SPECIAL MEETING WAS ADJOURNED *** PLEASE READ – YOUR VOTE IS NEEDED Dear Fellow NovaBay Stockholder: The Special Meeting of Stockholders of NovaBay Pharmaceuticals, Inc. (NYSE: NBY), has been adjourned until December 18, 2024 to provide stockholders additional time to vote on Proposal One and Proposal Two. Both proposals received significant support based on the shares that have been voted by stockholders, but have yet to reach the 50% threshold of favorable votes of all outstanding shares of common stock that is required to approve each of these proposals. Proposal One is a proposal to approve the sale of Avenova, representing substantially all of the assets of NovaBay (the "Asset Sale"), pursuant to the Asset Purchase Agreement, dated September 19, 2024, by and between NovaBay and PRN Physician Recommended Nutriceuticals, LLC, and Proposal Two is a proposal to approve the liquidation and dissolution of NovaBay pursuant to the Plan of Complete Liquidation and Dissolution of the Company (the "Plan of Dissolution") which, if approved, would authorize the Company to liquidate and dissolve in accordance with the Plan of Dissolution, and pursuant to the discretion of the Board of Directors to proceed with the dissolution. ISS, the leading proxy advisory firm, recommends voting in favor of Proposals One and Two. Your Board urges you to vote NOW ! Because of the higher required vote for Proposals One and Two, every stockholder's vote is important no matter how many shares you may own. Please submit your proxy as soon as possible. The fastest and easiest way to vote is by telephone or over the Internet. Instructions on how to vote your shares over the telephone or Internet are enclosed with this letter. Thank you for your investment in NovaBay and taking the time to vote your shares. Sincerely, Very truly yours, Justin M. Hall, Esq. Chief Executive Officer jhall@novabay.com NOVABAY PHARMACEUTICALS, INC. 2000 Powell St, Suite 1150, Emeryville, CA 94608 Phone: (510) 899-8870 Fax: (510) 255-0371